Heart drug colchicine may reveal new clues to fight inflammation

NCT ID NCT07462325

Not yet recruiting Knowledge-focused Sponsor: Chinese Academy of Medical Sciences, Fuwai Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how a low dose of colchicine, an anti-inflammatory drug, changes proteins in the blood of people with coronary heart disease and high inflammation. Researchers will compare protein levels before and after one month of treatment in 176 patients. The goal is to find new biomarkers and targets for future therapies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: colchicine
What this could lead to: If successful, this study could identify new protein targets for treating inflammation in heart disease, potentially leading to better therapies.
What could go wrong: This is an early exploratory study focused on protein changes, not on clinical outcomes. The results may not translate into effective treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CORONARY ARTERY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

coronary artery disorder Coronary Disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CORONARY ARTERY DISEASE CORONARY HEART DISEASE (CHD) PERCUTANEOUS CORONARY INTERVENTION (PCI) POST-PCI SYNDROME RESIDUAL INFLAMMATORY RISK

More trials for these conditions

Other studies related to the condition(s) this trial covers.